Biogen Names Christopher Viehbacher President and Chief Executive Officer

Biogen Names Christopher Viehbacher President and Chief Executive Officer

BiogenInc.( NASDAQ BIIB) moment blazoned that its Board of Directors has appointed ChristopherA. Viehbacher as President and Chief Executive Officer and a member of the Board of Directors, effective November 14. Viehbacher succeeds Michel Vounatsos, who has led the company since 2017.
Viehbacher has expansive transnational experience in both large pharmaceutical companies and entrepreneurial biotech companies. After 20 times with GlaxoSmithKline, he served as global CEO of Sanofi for six times, during which time the company crushed the loss of exclusivity of utmost of its portfolio and rotated to new sources of growth similar as Dupixent, which redounded from the cooperation with Regeneron, and in rare and specialty drugs following the accession of Genzyme. Under Viehbacher’s leadership, Sanofi strengthened and diversified its R&D channel and delivered significant value to shareholders.

More lately, Viehbacher and Ernesto Bertarellico-founded Gurnet Point Capital, a Cambridge- grounded healthcare investment fund, which has led to the creation and continuing development of numerous innovative companies. He has also chaired or been a member of the board of a number of entrepreneurial companies in biotechnology. Viehbacher has always been a strong advocate for invention and public health. He has entered a number of awards including the Légion d’Honneur from France.
Stelios Papadopoulos,Ph.D., Chairman of the Board of Biogen, said “ Chris is the rare pharma superintendent who has a keen understanding of the complications involved in running a multibillion- bone
global pharma business as well as a deep appreciation for the value of invention. It was the combination of these attributes that enabled him to turn around Sanofi and leave behind a much better company compared to the bone
he inherited. I look forward to Chris leading Biogen to the coming chapter of its elaboration and, on behalf of the board, I pledge our support to his trouble. ”

Viehbacher said “ It’s both an honor and an instigative occasion to join the Biogen platoon. I greatly respect Biogen for its determination and adaptability in introducing important new drugs to address some of the most delicate and grueling conditions in healthcare. I’m inspired by Biogen’s charge and untapped eventuality and look forward to working with the devoted Biogen platoon to make an indeed stronger company for the benefit of cases, stakeholders and investors. ”
Mr. Papadopoulos added, “ I want to thank Michel for his significant benefactions to Biogen and for his passionate commitment to our charge. He’ll be leaving Biogen with strong foundations for growth. We appreciate that Michel will remain employed by the company for a limited period of time to help insure a smooth transition. ”

Vounatsos said, “ It has been a honor to lead this great company and work with so numerous outstanding people for nearly six times. With 30 clinical programs, 12 of which are in Phase 3 or filed, Biogen is at an important curve point in CNS medicine discovery and development. I’m confident that Chris will be an excellent new leader of Biogen. With several implicit improvements in areas of high unmet requirements on the horizon, I believe the stylish is yet to come for Biogen and its cases. ”
About Biogen
As settlers in neuroscience, Biogen discovers, develops, and delivers worldwide innovative curatives for people living with serious neurological conditions as well as affiliated remedial closeness. One of the world’s first global biotechnology companies, Biogen was innovated in 1978 by Charles Weissmann, Heinz Schaller, Sir Kenneth Murray, and Nobel Prize winners Walter Gilbert and Phillip Sharp. moment, Biogen has a leading portfolio of drugs to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, and developed the first and only approved treatment to address a defining pathology of Alzheimer’s complaint. Biogen is also commercializing biosimilars and fastening on advancing one of the assiduity’s most diversified channels in neuroscience that will transfigure the standard of care for cases in several areas of high unmet need.

In 2020, Biogen launched a bold 20- time,$ 250 million action to address the deeply interrelated issues of climate, health, and equity. Healthy Climate, Healthy Lives ™ aims to exclude fossil energies across the company’s operations, make collaborations with famed institutions to advance the wisdom to ameliorate mortal health issues, and support underserved communities.

Source link: